Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vaxcyte Inc. Common Stock (PCVX) vs Taiwan Semiconductor Mfg. Co. Ltd. (TSM) Price & Performance

Vaxcyte Inc. Common StockTrade
Taiwan Semiconductor Mfg. Co. Ltd.Trade

Price performance (Past 24H)

Key statistics

Vaxcyte Inc. Common Stock vs Taiwan Semiconductor Mfg. Co. Ltd. — how do they compare? Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.51B), while Taiwan Semiconductor Mfg. Co. Ltd. trades at $423.29 (market cap $2.02T). The key difference: Taiwan Semiconductor Mfg. Co. Ltd. is far larger — about 192.2× Vaxcyte Inc. Common Stock's market cap, and Taiwan Semiconductor Mfg. Co. Ltd. pays a 0.91% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Taiwan Semiconductor Mfg. Co. Ltd. for 111 Days on average.

PCVXTSM
Market Cap
$10.51B$2.02T
Volume
2,644,6948,566,236
Sector
HealthTechnology
52-Week High
$73.82$485.80
52-Week Low
$40.32$275.06
Typical Hold Time
0 Days111 Days
Enterprise Value
$9.14B$1.94T
Dividend Yield
—0.91%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vaxcyte Inc. Common Stock

No Aura AI signal available yet.

Taiwan Semiconductor Mfg. Co. Ltd.

TSMC (TSM) trades at $445.12, up 0.17% on the day, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue and net income have shown robust growth, with 2025 revenue at $3.81T and net income at $1.70T. Analyst sentiment is overwhelmingly positive, with a consensus price target of $578.43, representing significant upside. Recent news highlights TSMC's pivotal role in AI chip manufacturing and upcoming dividend payments.

The outlook for TSM is favorable, driven by strong earnings momentum, high profitability margins, and its dominant position in semiconductor manufacturing. Key opportunities include continued AI-driven demand and technological leadership. Risks involve geopolitical tensions, competitive pressures, and market volatility. The stock presents a compelling long-term investment case supported by analyst optimism and solid financial health.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

PCVX
100% Buy0% Sell
Avg holding period · 0 Days
TSM
67% Buy33% Sell
Avg holding period · 111 Days

Top news

Latest headlines on both assets

About Vaxcyte Inc. Common Stock

Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.

Read more on PCVX →

About Taiwan Semiconductor Mfg. Co. Ltd.

Taiwan Semiconductor Manufacturing Company, or TSMC, is the world's largest dedicated chip foundry, with over 57% market share in 2021 per Gartner. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs.

Read more on TSM →